Skip to main content

HYQVIA Takeda Pharmaceuticals Australia Pty Ltd

Product name
HYQVIA
Accepted date
May-2024
Active ingredients
normal immunoglobulin
Proposed indication
For Immunomodulatory therapy in adults and children in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as maintenance therapy after stabilistion with IVIG.
Application type
C (new medicine)
Publication date
May-2024

Help us improve the Therapeutic Goods Administration site